NEW YORK – Based on promising results from two proof-of-concept studies presented at the virtual 2020 American Association for Cancer Research meeting earlier this week, Inivata believes that its RaDaR (Residual Disease and Recurrence) assay could be used to help monitor cancer patient relapse following curative treatment.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.